Calculated based on number of publications stored in Pure and citations from Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Dr Eadie is an award-winning biomedical researcher and the Peter Nelson Leukaemia Research Fellow, awarded to the top mid-career leukaemia researcher in South Australia (2019-current). She is a previous Fulbright scholar, a TEDx speaker and science communicator.

Dr Eadie has been awarded >$2.5 million in fellowship/grant funding since commencing her PhD from funding bodies including NHMRC, MRFF, Leukaemia Foundation, Cancer Council, Australian-American Fulbright Commission; the majority as CI-A. Laura has 8 years postdoctoral experience in the field of leukaemia research.

Dr Eadie is currently researching (since 2017) Acute Lymphoblastic Leukaemia (ALL), and is the T-ALL research leader. Dr Eadie is an emerging Australian leader in T-ALL genomics and modelling, most recently evidenced by an American Society of Hematology Achievement Award (2020). Her ALL research has resulted in 8 abstracts as presenting author (6 presentations at international meetings) and 8 publications including 3 invited reviews. She has published 19 peer-reviewed articles, cited 517 times (Google Scholar), 9 as first author and 5 in Leukemia (a top-5 discipline journal).

Public Profile

Research Focus 

Acute Lymphoblastic Leukaemia (ALL) is an extremely heterogeneous disease with subtypes of patients exhibiting a diverse range of genetic mutations. Certain subtypes of ALL can be treated with drugs already in clinical use. When undertaking her Fulbright fellowship (2016-2017) at St. Jude Children’s Research Hospital in Memphis, Tennessee, Dr Eadie trained with the global authority in genomic profiling and in vivo modelling of ALL. Since returning to Australia she has autonomously established preclinical mouse models of ALL at SAHMRI and is now leading in vivo mouse studies for high-risk ALL with a specific focus on T-cell ALL. Her research will assess targeted therapies in mouse models of ALL through ongoing generation of 1) patient derived xenografts from patient samples received in our laboratory and 2) transgenic models. This will enable the evaluation of novel and combination therapeutic approaches compared with the current standard of care. Mouse models of drug resistance will also be developed and pre-emptive intervention in the resistant disease setting investigated. These studies will ultimately inform clinical practice, impacting significantly on response to therapy and overall survival of adults and children with high-risk ALL. 

Education/Academic qualification

PhD, University of Adelaide

30 Mar 200927 Mar 2013

Award Date: 31 Jul 2013

Bachelor's Degree (Honours), University of Adelaide

17 Jan 20062 Dec 2006

Award Date: 20 Dec 2006

Bachelor's Degree, University of Adelaide

22 Jan 20032 Dec 2005

Award Date: 22 Dec 2005

External positions

Affiliate Senior Lecturer Discipline of Medicine, University of Adelaide

Apr 2020 → …

Post Doctoral Research Associate, St. Jude Children Research Hospital

14 Aug 201615 Aug 2017

Affiliate Lecturer Discipline of Medicine, University of Adelaide

Apr 2014Apr 2020


  • acute lymphoblastic leukaemia
  • mouse models
  • next generation sequencing
  • drug resistance
  • leukaemia


Recent external collaboration on country/territory level. Dive into details by clicking on the dots or